Comparative Pharmacology
Head-to-head clinical analysis: STRONTIUM CHLORIDE SR 89 versus XOFIGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STRONTIUM CHLORIDE SR 89 versus XOFIGO.
STRONTIUM CHLORIDE SR-89 vs XOFIGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Strontium-89 is a calcium mimetic that localizes to bone, particularly areas of increased osteoblastic activity, emitting beta radiation that causes DNA damage and cell death in metastatic tumor cells.
Radium-223 dichloride is a calcium-mimetic alpha particle-emitting radiopharmaceutical that forms complexes with bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases. The alpha particles induce double-strand DNA breaks in adjacent cells, resulting in cytotoxic effects.
148 MBq (4 mCi) intravenously over 1-2 minutes, single dose. Repeat after 3-6 months if needed.
55 kBq (1.49 microcurie) per kg body weight, intravenous injection every 4 weeks.
None Documented
None Documented
Terminal elimination half-life: 50.5 days (range 33–65 days). Reflects slow clearance from bone; clinical effect persists due to long skeletal retention.
The terminal elimination half-life of radium-223 dichloride is approximately 11 days (range 7–14 days), reflecting the slow turnover of radium in bone.
Primarily renal (urinary) excretion; approximately 50-80% of absorbed dose eliminated via urine over 7 days. Fecal elimination is negligible (<5%).
Radium-223 dichloride is primarily excreted via the feces. Approximately 75% of the administered dose is eliminated in feces within 7 days, with a smaller fraction (about 5%) excreted in urine.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical